+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Influenza Vaccine Market by Vaccine Type, Distribution Channel, End User, Age Group, Dosage, Presentation - Global Forecast to 2030- Product Image
Influenza Vaccine Market by Vaccine Type, Distribution Channel, End User, Age Group, Dosage, Presentation - Global Forecast to 2030- Product Image
Sale

Influenza Vaccine Market by Vaccine Type, Distribution Channel, End User, Age Group, Dosage, Presentation - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5012972
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Influenza Vaccine Market grew from USD 8.61 billion in 2024 to USD 9.41 billion in 2025. It is expected to continue growing at a CAGR of 9.06%, reaching USD 14.50 billion by 2030.

Setting the Stage for an Evolving Influenza Vaccine Landscape

This executive summary offers a comprehensive overview of the influenza vaccine market as it stands entering 2025. It synthesizes current immunization strategies, regulatory landscapes, and evolving patient preferences to provide a lucid foundation for industry stakeholders. By distilling complex trends and emerging technologies, this summary equips decision-makers with the insights needed to navigate competitive pressures and public health imperatives.

Beginning with the interplay of policy, production, and demand, the following sections examine the transformative shifts reshaping vaccine development and distribution. Stakeholders will gain clarity on how geopolitical factors, such as trade tensions and tariff regimes, influence supply chain resilience and cost dynamics. In turn, these insights pave the way for strategic segmentation analysis and regional intelligence that inform targeted growth strategies across diverse market segments.

Transformative Shifts Reshaping Influenza Vaccination Approaches

The influenza vaccine landscape is undergoing a seismic transformation driven by technological breakthroughs, shifting public health priorities, and innovative delivery models. Recombinant and mRNA-based approaches are accelerating development timelines, while traditional egg-based methods continue to evolve through process optimization and capacity expansion. Public-private partnerships have become instrumental in funding advanced research, and regulatory agencies are streamlining pathways for next-generation formulations.

Innovation extends beyond antigen design to encompass digital health platforms that monitor immunization uptake and real-world effectiveness. Advanced analytics and artificial intelligence are enabling predictive modeling for seasonal strain selection, helping manufacturers anticipate demand and adapt production schedules. Meanwhile, emerging cross-sector collaborations between diagnostics developers and vaccine companies are laying the groundwork for integrated respiratory disease management solutions.

Simultaneously, heightened awareness of co-infection risks and the convergence of pandemic preparedness with seasonal vaccination programs have prompted health systems to adopt more coordinated immunization strategies. Multi-dose clinics, mobile vaccination units, and home administration kits are bridging access gaps, while targeted outreach campaigns address vaccine hesitancy through transparent communication and community engagement. These shifts are redefining the end-to-end vaccination experience and setting new benchmarks for program effectiveness.

Assessing the Ripple Effects of US Tariffs on Vaccine Supply Chains

In 2025, the introduction of reciprocal tariffs on pharmaceutical imports has triggered a cascade of adjustments across the influenza vaccine market. Manufacturers sourcing key raw materials from international suppliers are facing elevated costs that ultimately influence vaccine pricing structures and profit margins. These tariffs have prompted vaccine developers to reassess supply chain configurations, seeking alternative production hubs to mitigate exposure to trade barriers.

The pass-through of tariff-related expenses to end users has heightened scrutiny from healthcare payers and public sector buyers, who are demanding more transparent pricing models. Negotiations between manufacturers and large-scale procurement agencies have shifted toward value-based contracting and volume guarantees as a means to offset added financial burdens. This dynamic has intensified competition among vaccine suppliers vying for preferred status in government immunization programs.

On the manufacturing front, the tariff landscape has accelerated collaborative endeavors aimed at localizing production. Investment in domestic bioreactor capacity and fill-finish facilities has become a strategic imperative, reducing dependency on cross-border shipments. As a result, some emerging players are poised to capture market share by aligning their operational footprint with regions less affected by trade escalations, thereby offering competitive pricing and enhanced supply assurance.

Unveiling Critical Market Segmentation Dimensions for Influenza Vaccines

When examining vaccine type segmentation, the market encompasses inactivated formulations, live attenuated options, and recombinant products, each aligned with specific manufacturing processes and immunogenic profiles. Transitioning to distribution channel analysis reveals that hospital pharmacies, online pharmacies, and retail outlets drive accessibility. Within retail, chains deliver consistent volume while independent pharmacies offer adaptable service models tailored to local immunization campaigns.

Delving into end-user categories, outpatient and specialty clinics serve high-touch vaccination programs, whereas home healthcare delivered via professional nursing services or self-administration kits addresses patient-centric convenience. Hospitals, both private and public, maintain critical cold chain infrastructure for mass immunization drives, supporting robust seasonal campaigns and pandemic preparedness alike. Population segmentation underscores divergent needs across adult, geriatric, and pediatric cohorts, influencing dosage strategies that range from single-dose prefilled syringes to multi-dose vials.

Consideration of dosage structure highlights a balance between multi-dose presentations, which optimize inventory turnover in large-scale settings, and single-dose formats that minimize wastage and support compliance in outpatient environments. These choices intersect with presentation preferences, as glass and plastic prefilled syringes deliver high-precision dosing at the point of care, while multi-dose and single-dose vials provide scalable supply for diverse vaccination centers, reinforcing both cost-efficiency and operational agility.

Regional Dynamics Driving Influenza Vaccine Adoption Worldwide

In the Americas, robust immunization initiatives in the United States and Canada continue to set benchmarks for influenza vaccine uptake, underpinned by established seasonal campaigns and extensive public-private partnerships. Latin American markets display varied adoption rates influenced by national procurement policies, economic constraints, and emerging cold chain investments aimed at rural outreach.

Europe, the Middle East and Africa present a mosaic of regulatory frameworks and payer systems that drive both innovation and cost containment. Western European nations prioritize high-efficacy formulations and sophisticated distribution networks. Gulf Cooperation Council countries are scaling localized manufacturing capacity through strategic collaborations, while Sub-Saharan Africa grapples with infrastructure challenges but benefits from targeted donor-funded campaigns that boost pediatric coverage.

In the Asia-Pacific region, expansive populations and rising healthcare expenditures are catalyzing vaccine uptake across China, Japan, India, and Southeast Asian nations. The proliferation of e-commerce platforms is enhancing reach in remote communities, and regulatory harmonization efforts are streamlining approvals for next-generation vaccine platforms. Demand is further fueled by government-backed immunization programs seeking to alleviate seasonal influenza burden and strengthen pandemic preparedness.

Strategic Insights on Market-Leading Influenza Vaccine Companies

Market-leading manufacturers continue to refine their portfolios through platform diversification and strategic alliances. Sanofi’s investment in recombinant egg-free production exemplifies its pursuit of scalable and flexible manufacturing methodologies. GlaxoSmithKline expands its live attenuated vaccine offerings to address both pediatric and adult immunization needs, reinforcing its position in seasonal influenza markets.

Pfizer’s commitment to mRNA-based vaccine research signals a long-term strategy for rapid response to antigenic drift, while Moderna leverages its proprietary mRNA platform to streamline development and regulatory pathways. AstraZeneca’s network of contract manufacturing partners enhances supply continuity, a critical factor in tariff-impacted environments and fluctuating demand cycles.

Specialized players such as Seqirus focus on dose-sparing adjuvant technologies and niche delivery systems, enabling differentiated value propositions. Across the competitive landscape, strategic mergers, licensing agreements, and equity partnerships are accelerating time to market for advanced formulations, underscoring the importance of collaboration in sustaining growth and meeting evolving public health objectives.

Actionable Recommendations to Strengthen Vaccine Market Positioning

Industry leaders should prioritize the acceleration of recombinant and mRNA platforms to shorten development cycles and address antigenic variability with unprecedented agility. Simultaneously, diversifying raw material procurement through a blend of regional and alternative sourcing hubs will hedge against geopolitical disruptions and tariff-related cost pressures. Enhancing digital demand forecasting and inventory optimization will further fortify supply chain resilience and align production with real-time immunization trends.

Collaborative engagement with retail and online pharmacy networks can streamline patient access and foster data-driven adherence programs. Investing in age-specific delivery devices and tailored dosing regimens will differentiate product portfolios in a crowded market, while strategic partnerships with public health authorities can amplify immunization campaign reach and reinforce trust. Finally, embedding sustainability initiatives within manufacturing and distribution processes will resonate with payers and end users increasingly focused on environmental stewardship.

Robust Research Methodology Underpinning Market Analysis

This analysis is grounded in a multi-faceted research framework that integrates secondary data from regulatory filings, peer-reviewed literature and industry publications. Complementing desk research, primary insights were obtained through in-depth discussions with vaccine developers, supply chain experts and healthcare providers across key markets.

Quantitative data points underwent rigorous triangulation to validate consistency across sources, while qualitative feedback from senior executives informed nuanced interpretation of competitive dynamics and emerging technology adoption. This hybrid approach ensures a balanced and robust perspective on the complex forces shaping the influenza vaccine market.

Synthesizing Core Findings to Inform Strategic Decisions

The influenza vaccine market in 2025 reflects a convergence of technological innovation, strategic segmentation and geopolitical considerations. Transformative platform advances and evolving patient delivery models are unlocking new pathways for growth, even as tariff regimes impose fresh cost and operational challenges. Stakeholders who navigate these dynamics proactively will secure competitive advantage in diverse immunization landscapes.

By integrating granular segmentation insights with targeted regional intelligence and company-focused strategies, organizations can optimize product offerings and distribution networks to meet shifting demand patterns. The actionable recommendations outlined herein provide a blueprint for fortifying research pipelines, enhancing supply chain resilience and fostering collaborative ecosystems that elevate immunization outcomes.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Vaccine Type
    • Inactivated
    • Live Attenuated
    • Recombinant
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
      • Chain
      • Independent
  • End User
    • Clinics
      • Outpatient Clinics
      • Specialty Clinics
    • Home Healthcare
      • Home Nurses
      • Self-Administration
    • Hospitals
      • Private Hospitals
      • Public Hospitals
  • Age Group
    • Adult
    • Geriatric
    • Pediatric
  • Dosage
    • Multi Dose
    • Single Dose
  • Presentation
    • Prefilled Syringe
      • Glass Prefilled Syringe
      • Plastic Prefilled Syringe
    • Vial
      • Multi Dose Vial
      • Single Dose Vial
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Sanofi S.A.
  • CSL Limited
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Pfizer Inc.
  • Sinovac Biotech Ltd.
  • China National Pharmaceutical Group Co., Ltd.
  • Serum Institute of India Private Limited
  • Changchun BCH Bioengineering Co., Ltd.
  • Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Influenza Vaccine Market, by Vaccine Type
8.1. Introduction
8.2. Inactivated
8.3. Live Attenuated
8.4. Recombinant
9. Influenza Vaccine Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
9.4.1. Chain
9.4.2. Independent
10. Influenza Vaccine Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. Outpatient Clinics
10.2.2. Specialty Clinics
10.3. Home Healthcare
10.3.1. Home Nurses
10.3.2. Self-Administration
10.4. Hospitals
10.4.1. Private Hospitals
10.4.2. Public Hospitals
11. Influenza Vaccine Market, by Age Group
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Influenza Vaccine Market, by Dosage
12.1. Introduction
12.2. Multi Dose
12.3. Single Dose
13. Influenza Vaccine Market, by Presentation
13.1. Introduction
13.2. Prefilled Syringe
13.2.1. Glass Prefilled Syringe
13.2.2. Plastic Prefilled Syringe
13.3. Vial
13.3.1. Multi Dose Vial
13.3.2. Single Dose Vial
14. Americas Influenza Vaccine Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Influenza Vaccine Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Influenza Vaccine Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Sanofi S.A.
17.3.2. CSL Limited
17.3.3. GlaxoSmithKline plc
17.3.4. AstraZeneca plc
17.3.5. Pfizer Inc.
17.3.6. Sinovac Biotech Ltd.
17.3.7. China National Pharmaceutical Group Co., Ltd.
17.3.8. Serum Institute of India Private Limited
17.3.9. Changchun BCH Bioengineering Co., Ltd.
17.3.10. Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. INFLUENZA VACCINE MARKET MULTI-CURRENCY
FIGURE 2. INFLUENZA VACCINE MARKET MULTI-LANGUAGE
FIGURE 3. INFLUENZA VACCINE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. INFLUENZA VACCINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. INFLUENZA VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. INFLUENZA VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY CHAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOME NURSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SELF-ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GLASS PREFILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PLASTIC PREFILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 72. CANADA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 73. CANADA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. CANADA INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 75. CANADA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. CANADA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 77. CANADA INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 78. CANADA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 79. CANADA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 80. CANADA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 81. CANADA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 82. CANADA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 83. CANADA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 84. MEXICO INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 85. MEXICO INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. MEXICO INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 87. MEXICO INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. MEXICO INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 90. MEXICO INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 91. MEXICO INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 92. MEXICO INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 93. MEXICO INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 94. MEXICO INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 95. MEXICO INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 145. GERMANY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 146. GERMANY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. GERMANY INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 148. GERMANY INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. GERMANY INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 150. GERMANY INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 151. GERMANY INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 152. GERMANY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 153. GERMANY INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 154. GERMANY INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 155. GERMANY INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 156. GERMANY INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 157. FRANCE INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 158. FRANCE INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. FRANCE INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 160. FRANCE INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. FRANCE INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 162. FRANCE INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 163. FRANCE INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 164. FRANCE INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 165. FRANCE INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 166. FRANCE INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 167. FRANCE INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 168. FRANCE INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 169. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 170. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 172. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 178. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 181. ITALY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 182. ITALY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. ITALY INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 184. ITALY INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. ITALY INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 186. ITALY INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 187. ITALY INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 188. ITALY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 189. ITALY INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 190. ITALY INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 191. ITALY INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 192. ITALY INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 193. SPAIN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 194. SPAIN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. SPAIN INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 196. SPAIN INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. SPAIN INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 198. SPAIN INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 199. SPAIN INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 200. SPAIN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 201. SPAIN INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 202. SPAIN INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 203. SPAIN INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 204. SPAIN INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 205. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 206. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 208. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 217. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 218. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 220. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 222. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 224. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 226. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 229. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 230. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 232. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 241. DENMARK INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 242. DENMARK INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. DENMARK INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 244. DENMARK INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. DENMARK INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 246. DENMARK INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 247. DENMARK INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 248. DENMARK INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 249. DENMARK INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 250. DENMARK INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 251. DENMARK INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 252. DENMARK INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 253. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 254. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 256. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 265. QATAR INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 266. QATAR INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. QATAR INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 268. QATAR INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. QATAR INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 270. QATAR INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 271. QATAR INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 272. QATAR INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 273. QATAR INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 274. QATAR INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 275. QATAR INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 276. QATAR INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 277. FINLAND INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 278. FINLAND INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. FINLAND INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 280. FINLAND INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. FINLAND INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 282. FINLAND INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 283. FINLAND INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 284. FINLAND INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 285. FINLAND INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 286. FINLAND INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 287. FINLAND INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 288. FINLAND INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 289. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 290. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 292. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 294. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 301. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 302. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 304. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 306. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 307. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 308. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 309. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 310. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 311. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 312. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 313. EGYPT INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 314. EGYPT INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 315. EGYPT INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 316. EGYPT INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 317. EGYPT INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 318. EGYPT INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 319. EGYPT INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 320. EGYPT INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 321. EGYPT INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 322. EGYPT INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 323. EGYPT INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 324. EGYPT INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 325. TURKEY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 326. TURKEY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 327. TURKEY INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 328. TURKEY INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 329. TURKEY INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 330. TURKEY INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 331. TURKEY INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 332. TURKEY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 333. TURKEY INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 334. TURKEY INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 335. TURKEY INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 336. TURKEY INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 337. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 338. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 339. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 340. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 341. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 342. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 343. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 344. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 345. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 346. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2030 (USD MILLION)
TABLE 347. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 348. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 349. NORWAY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 350. NORWAY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 351. NORWAY INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 352. NORWAY INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 353. NORWAY INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 354. NORWAY INFLUENZA VACCINE MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 355. NORWAY INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Influenza Vaccine market report include:
  • Sanofi S.A.
  • CSL Limited
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Pfizer Inc.
  • Sinovac Biotech Ltd.
  • China National Pharmaceutical Group Co., Ltd.
  • Serum Institute of India Private Limited
  • Changchun BCH Bioengineering Co., Ltd.
  • Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages190
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 9.41 Billion
Forecasted Market Value ( USD ) by 2030 $ 14.5 Billion
Compound Annual Growth Rate9.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Influenza Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Influenza Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Influenza Vaccines Market Opportunities and Strategies to 2033 - Product Image

Influenza Vaccines Market Opportunities and Strategies to 2033

  • Report
  • 291 Pages
  • Global
From
Influenza Vaccine Market Report by Vaccine Type, Technology, Age Group, Route of Administration, and Region 2024-2032 - Product Image

Influenza Vaccine Market Report by Vaccine Type, Technology, Age Group, Route of Administration, and Region 2024-2032

  • Report
  • 138 Pages
  • Global
From
Influenza Vaccine Market 2024-2028 - Product Image

Influenza Vaccine Market 2024-2028

  • Report
  • 168 Pages
  • Global
From
Influenza Vaccines - Global Strategic Business Report - Product Image

Influenza Vaccines - Global Strategic Business Report

  • Report
  • 554 Pages
  • Global
From

About the Market

The Flu Vaccine market is a subset of the larger Vaccines market, which is composed of products designed to prevent and treat infectious diseases. Flu Vaccines are specifically designed to protect against influenza, a highly contagious virus that can cause severe illness and even death. Flu Vaccines are typically administered annually, and are recommended for people of all ages, including pregnant women and those with chronic health conditions. Flu Vaccines are typically developed by pharmaceutical companies, and are then approved and distributed by government health agencies. In addition to traditional flu vaccines, there are also recombinant vaccines, which are produced using genetic engineering techniques. Companies in the Flu Vaccine market include Sanofi Pasteur, GlaxoSmithKline, Merck & Co., Pfizer, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.